Journal of Okayama Medical Association
Published by Okayama Medical Association

<Availability>
Full-text articles are available 3 years after publication.

腫瘍細胞と正常細胞との融合細胞による特異的抗腫瘍免疫の誘導

廣瀬 清 岡山大学医学部第一外科学教室
Thumnail 99_931.pdf 1.67 MB
抄録
Six hybrid cell clones were obtained by the fusion of Meth-A sarcoma cells (BALB/c mouse origin) and L(AG) cells (C3H mouse fibroblast) with the use of PEG 4000. The clones, named L-Me-A, B, C, D, E and F, were tested for their anti-tumor effects in mice. Each hybrid cell clone expressed both Meth-A sarcoma cell antigen and L(AG) cell antigen. Though each hybrid cell clone showed 51-88% of Meth-A sarcoma cell antigen, none of the clones produced tumors in normal BALB/c mice after s.c. inoculation of 10(6) cells. Normal BALB/c mice pretreated weekly with viable 10(6) L-Me-C cells for three weeks showed specific resistance to a challenge of Meth-A sarcoma cells. In the Winn assay, anti-tumor activity was observed in immune spleen cells and was lost by treatment with anti-Thy-1.2 antibody or anti-Lyt-1.2 antibody and complement, but not by treatment with anti-Lyt-2.2 antibody and complement. Adoptive transfer of this immune spleen cell fraction (Thy-1(+), Lyt-1(+)2(-) cells) to Meth-A sarcoma bearing mice was effective against tumor growth, too. Furthermore, inoculations of L-Me-C cells in BALB/c mice bearing Meth-A sarcomas depressed tumor growth remarkably. These results indicate that the anti-tumor immunity induced by hybrid cells was produced by Thy-1(+), Lyt-1(+)2(-) cells. It may be possible to apply this anti-tumor immunity not only to the prophylactic protection of normal hosts against the challenge of parental tumor but also to the therapy of hosts bearing parental tumors.
キーワード
特異的抗腫瘍免疫
細胞融合
雑種細胞(hybrid cell)
Thy-1(+)
Lyt-1(+)2(-) cell
Adoptive transfer
ISSN
0030-1558
NCID
AN00032489